Navigation Links
BIOCRATES Life Sciences to Launch Waters Xevo® TQ MS Editions for Two of its Well-established Research Kit Products, AbsoluteIDQ® p180 and p150
Date:5/21/2012

VIENNA, May 21, 2012 /PRNewswire/ --

Austrian BIOCRATES Life Sciences AG, prime developer of state-of-the-art metabolite biomarker panels, is about to launch new editions of two of its well-established research kit products -AbsoluteIDQ® p180 and p150. Originally developed for use with the AB Sciex mass spectrometers, both kits are now available for Waters Xevo® TQ MS systems,  greatly increasing sample throughput and accelerating up analytical processes.

AbsoluteIDQ® p180 Kit-Waters Xevo® TQ MS edition
Now also running on the ACQUITY UPLC® system by Waters, the new edition of the AbsoluteIDQ  p180 Kit speeds up your research, requiring only 16 hours of measurement time compared with 32 hours for conventional high performance liquid chromatography (HPLC). The Waters UPLC® technology was created especially for scientists who seek a reliable technology that simultaneously improves laboratory productivity, efficiency, and throughput.

Quantifying more than 180 metabolites from key metabolic pathways, the AbsoluteIDQ p180 Kit delivers the widest range of metabolomic information available from a single targeted assay. Analyzed metabolite classes include acylcarnitines, amino acids and biogenic amines, hexose, and sphingo- and glycerophospholipids.

AbsoluteIDQ® p150 Kit-Waters Xevo® TQ MS edition
Also now available for Waters Xevo TQ mass spectrometers is the AbsoluteIDQ p150 Kit, which identifies and quantifies 158 metabolites from 4 compound classes using a FIA-MS/MS method.

Both kits feature the proprietary MetIDQ™ software for the automated calculation of metabolite concentrations, require only small sample volumes of 10 µL, and are suitable for use with a wide range of biological samples.

About BIOCRATES
BIOCRATES Life Sciences AG is a leading biotechnology company focused on biomarker discovery and the development of  MS-based standardized metabolomics kits as well as in vitro diagnostics (IVDs). Please visit us at http://www.biocrates.com.

For questions: Michael Leitner, Public Health PR
Tel.: +43-1-602-05-30-92, e-mail: michael.leitner@publichealth.at


'/>"/>
SOURCE Biocrates Life Sciences AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
2. Egalet to Present at Life Sciences Europe Conference
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
5. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
6. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
7. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 17, 2017  Bayer ... growing oncology portfolio will be presented at the 53 ... Clinical Oncology (ASCO), taking place June 2-6 in ... being presented at ASCO span prostate, colorectal, liver and ... subgroup analysis from the Phase II CHRONOS-1 trial of ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/27/2017)... , ... May 26, 2017 , ... A May 8 ... visit a doctor for colds or respiratory issues that are not responsive to antibiotics ... pressure on doctors may be largely responsible for the problem both in Canada and ...
(Date:5/27/2017)... ... 2017 , ... Most us are familiar with the sound of occasional popping ... Osteoarthritis Initiative shows that certain people who experience consistent joint popping, grating and ... doctors the opportunity to treat patients before the problem becomes pronounced, potentially hedging off ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... new educational seminar to focus on current legislative activity and the latest regulatory ... at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, ...
(Date:5/26/2017)... Fla. (PRWEB) , ... May 26, 2017 , ... ... of premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that ... your menus. , “Boar’s Head fresh sliced meats and cheeses featured in ...
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... Agreements being discussed by President Donald Trump and the rest of the world. Donald ... up peace talks in the continuous battle between Israel and Palestine. The world’s eyes ...
Breaking Medicine News(10 mins):